Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.
Sold as Imuran. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 16, 2026, FDA lists 3 applications for Azathioprine Sodium (sold as Imuran), first approved Jul 19, 1974, with 0 new uses approved and 0 published complete response letters.
First approved: Jul 19, 1974
Applications: 3
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $0K
First approved in the EU: Jun 21, 2021
Medicare Spending
CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name
Product
Part
Spending, 2025
Change
Beneficiaries
Azathioprine Sodium
Part D
$0K
-100%
0
What Pharmacies Pay
Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change
AZATHIOPRINE 100 MG TABLET: $3.44 per unitGeneric · -27% in a year
AZATHIOPRINE 50 MG TABLET: $0.128 per unitGeneric · -6% in a year
AZATHIOPRINE 75 MG TABLET: $6.90 per unitGeneric · -42% in a year
ImuranDrugs with a new additional indication for the treatment of autoimmune hepatitis. · Mitsubishi Tanabe Pharma Corporation · Feb 21, 2019
ImuranDrugs with new additional indications and a new dosage for the treatment of the following treatment- resistant rheumatic diseases: systemic vasculitis… · Mitsubishi Tanabe Pharma Corporation · May 20, 2011
Clinical Trials
60 open or ongoing studies name this ingredient as an intervention, including as a comparator; newest first. See all
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient.Drugs@FDA